8-K: Schrodinger Q2 2025: Revenue Up, OpEx Down

Schrodinger, Inc. reported a 16% increase in Q2 2025 total revenue to $54.8 million, maintained full-year revenue guidance, and lowered operating expense guidance.

Summary

• Total revenue for the second quarter of 2025 increased 16% to $54.8 million, compared to $47.3 million in the second quarter of 2024.
• Software revenue for the second quarter increased 15% to $40.5 million, compared to $35.4 million in the second quarter of 2024.
• Drug discovery revenue was $14.2 million for the second quarter, compared to $11.9 million in the second quarter of 2024.
• Software gross margin was 68% for the second quarter, compared to 80% in the second quarter of 2024, primarily reflecting costs associated with the company's predictive toxicology initiative.
• Operating expenses were $79.1 million for the second quarter, a 6% decrease compared to $84.1 million for the second quarter of 2024, due to lower R&D expenses.
• Net loss for the second quarter was $43.2 million, an improvement from $54.0 million in the second quarter of 2024.
• Non-GAAP net loss for the second quarter was $47.5 million, compared to $48.1 million for the second quarter of 2024.
• Full-year 2025 software revenue growth guidance is maintained at 10% to 15%.
• Full-year 2025 drug discovery revenue guidance is maintained at $45 million to $50 million.
• Full-year 2025 software gross margin guidance is maintained at 74% to 75%.
• Operating expenses in 2025 are now expected to be lower than 2024.
• Cash used for operating activities in 2025 is expected to be significantly lower than cash used in 2024.
• For the third quarter of 2025, software revenue is expected to range from $36 million to $40 million.
• Initial Phase 1 clinical data for SGR-1505, the company's MALT1 inhibitor, showed it was well tolerated and clinically active with responses observed in multiple histologies, including chronic lymphocytic leukemia and Waldenstrm macroglobulinemia.
• SGR-1505 received Fast Track Designation from the FDA for the treatment of adult patients with Waldenstrm macroglobulinemia that have failed at least two lines of therapy, including a BTK inhibitor.
• The company is exploring strategic opportunities for SGR-1505 with goals of accelerating clinical development and maximizing patient benefit.
• Initial clinical data for SGR-3515 (Wee1/Myt1 co-inhibitor) and SGR-2921 (CDC7 inhibitor) are expected in the fourth quarter of 2025.
• An expanded research collaboration with Ajax Therapeutics, a company co-founded by Schrdinger, was announced, adding a new Janus kinase (JAK) target.
• A review of the organization was completed in May, resulting in a reduction in force of approximately 7% of full-time employees, expected to reduce operating expenses by approximately $30 million on an annualized basis.
• New appointments include Richie Jain as Chief Financial Officer and Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing; Karen Akinsanya's role was expanded to President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships.

Sentiment

Score: 7

Explanation: The company demonstrated solid revenue growth and improved net loss while proactively managing operating expenses through a workforce reduction. Positive clinical data for SGR-1505 and Fast Track designation are significant milestones. The maintained full-year guidance and lowered operating expense outlook suggest a stable financial trajectory. However, the decline in software gross margin and continued net losses temper the overall sentiment.

Positives

• Total revenue increased 16% to $54.8 million in Q2 2025, demonstrating strong growth.
• Software revenue increased 15% to $40.5 million in Q2 2025, indicating robust demand for computational technologies.
• Drug discovery revenue increased 19% to $14.2 million in Q2 2025, showing progress in collaborative programs.
• Net loss improved to $43.2 million in Q2 2025 from $54.0 million in Q2 2024, reflecting better financial performance.
• Operating expenses decreased by 6% to $79.1 million in Q2 2025 due to lower R&D, indicating effective cost management.
• Full-year 2025 operating expense guidance was lowered, now expected to be lower than 2024, signaling continued cost control.
• Cash used for operating activities in 2025 is expected to be significantly lower than 2024, improving cash flow outlook.
• Encouraging initial Phase 1 clinical data for SGR-1505 showed it was well tolerated and clinically active with responses in B-cell malignancies.
• SGR-1505 received Fast Track Designation from the FDA for Waldenstrm macroglobulinemia, potentially accelerating its development and review.
• Expanded research collaboration with Ajax Therapeutics adds a new JAK target, providing potential for future milestones and royalties.
• Organizational changes, including a 7% reduction in force, are expected to reduce operating expenses by approximately $30 million annually, enhancing efficiency.
• Other income was $10.0 million in Q2 2025, a significant positive swing from an expense of $1.2 million in Q2 2024.

Negatives

• Software gross margin decreased to 68% in Q2 2025 from 80% in Q2 2024, primarily due to costs associated with the predictive toxicology initiative.
• The company continues to report a net loss of $43.2 million and a non-GAAP net loss of $47.5 million, indicating ongoing unprofitability.

Risks

• Demand for the software platform may fluctuate.
• Ability to further develop the computational platform is uncertain.
• Reliance upon third-party providers of cloud-based infrastructure to host software solutions poses operational risks.
• Factors adversely affecting the life sciences industry could impact business.
• Fluctuations in the value of the U.S. dollar and foreign currencies may affect financial results.
• Reliance upon third-party drug discovery collaborators introduces dependency risks.
• Uncertainties inherent in drug development and commercialization, including the timing and ability to initiate and complete preclinical studies and clinical trials.
• Results from preclinical studies may not be predictive of the results of later preclinical studies and clinical trials.
• Uncertainties associated with the regulatory review of IND submissions, clinical trials, and applications for marketing approvals.
• Ability to retain and hire key personnel is crucial for continued operations and growth.
• Other risks detailed in the company's Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025.

Future Outlook

Schrdinger maintains its full-year 2025 software revenue growth guidance of 10% to 15% and drug discovery revenue guidance of $45 million to $50 million. Software gross margin is expected to range from 74% to 75%. Operating expenses in 2025 are now expected to be lower than 2024, and cash used for operating activities is expected to be significantly lower than 2024. For Q3 2025, software revenue is projected to be between $36 million and $40 million. The company anticipates reporting initial clinical data for SGR-3515 and SGR-2921 in Q4 2025 and plans to complete the Phase 1 package for SGR-1505 and meet with the FDA later this year to discuss the recommended Phase 2 dose.

Management Comments

• "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven computational technologies to accelerate molecular discovery." Ramy Farid, Ph.D., Chief Executive Officer.
• "We are very pleased with the initial Phase 1 SGR-1505 data we presented last month at EHA and ICML. We are exploring strategic opportunities for SGR-1505 with the goals of accelerating the clinical development of this potential best-in-class molecule and maximizing benefit to patients globally." Karen Akinsanya, Ph.D., President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships.
• "In parallel, we plan to complete the Phase 1 package and meet with the FDA later this year to discuss the recommended Phase 2 dose." Karen Akinsanya, Ph.D.

Industry Context

The filing underscores the growing reliance on advanced computational platforms, including AI and physics-based methods, for molecular discovery and drug development within the life sciences industry. Schrdinger's continued revenue growth in software and drug discovery, coupled with its expanded collaboration with Ajax Therapeutics and publication with major pharmaceutical companies like Sanofi, Galapagos, and UCB, highlights its position as a key enabler in this evolving landscape. The focus on clinical-stage oncology programs (MALT1, CDC7, Wee1/Myt1 inhibitors) aligns with the significant investment and high unmet medical needs in cancer therapeutics, where computational approaches are increasingly critical for identifying novel and optimized molecules.

Comparison to Industry Standards

• The company's collaboration with industry leaders such as Sanofi, Galapagos, and UCB, leading to a publication in the Journal of Medicinal Chemistry on computational hit-finding, suggests that Schrdinger's physics-based methods, including FEP+, are recognized and utilized by major pharmaceutical companies, indicating a high standard of scientific rigor and utility.
• SGR-1505 is described as a 'potential best-in-class molecule' for MALT1 inhibition in B-cell malignancies, including Waldenstrm macroglobulinemia and chronic lymphocytic leukemia. While specific comparable companies or competing molecules are not named, this designation implies that Schrdinger aims to set a new benchmark against existing or developing therapies in this therapeutic area.

Management Changes

Corporate Governance

Related Party Transactions

• Expanded research collaboration with Ajax Therapeutics, a company co-founded by Schrdinger, adding a new Janus kinase (JAK) target.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth, improved net loss, lowered operating expense guidance, and significant clinical pipeline progress (SGR-1505 data, Fast Track, future data). Potential for value creation from strategic opportunities for SGR-1505.
• Employees: Negative impact from a 7% reduction in force, but positive for remaining employees due to improved operating efficiency and potential for long-term company stability.
• Customers (Software): Continued strong demand for computational technologies, indicating stable relationships and value proposition.
• Collaborators (Drug Discovery): Continued and expanded collaborations (e.g., Ajax Therapeutics) indicate strong partnerships and mutual benefit.
• Creditors: Improved cash burn outlook and reduced net loss could signal better financial health and reduced credit risk.

Next Steps

• Complete the Phase 1 data package for SGR-1505.
• Meet with the FDA later this year to discuss the recommended Phase 2 dose for SGR-1505.
• Explore strategic opportunities for the continued clinical development of SGR-1505.
• Report initial clinical data from the Phase 1 clinical study of SGR-2921 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in the fourth quarter of 2025.
• Report initial clinical data from the Phase 1 clinical study of SGR-3515 in patients with advanced solid tumors in the fourth quarter of 2025.

Key Dates

Recommendation

While Schrodinger demonstrated solid revenue growth, improved net loss, and proactive cost management, the company continues to operate at a net loss, and the software gross margin declined. The positive clinical data for SGR-1505 and Fast Track designation are significant, but the company is still exploring strategic opportunities for its development, indicating potential future uncertainty or dilution. The stock may see short-term positive movement due to the news, but the long-term profitability and successful commercialization of its drug pipeline remain key factors for a stronger recommendation. For now, it's prudent to hold and monitor the progress of their clinical programs and the outcome of strategic discussions for SGR-1505.

Keywords

Computational drug discovery, AI in drug development, Molecular discovery, Software platform, Biotechnology, Pharmaceutical, Oncology, MALT1 inhibitor, CDC7 inhibitor, Wee1/Myt1 co-inhibitor, SGR-1505, SGR-2921, SGR-3515, B-cell malignancies, Waldenstrm macroglobulinemia, Acute myeloid leukemia, Myelodysplastic syndrome, Advanced solid tumors, Fast Track Designation, Ajax Therapeutics, Janus kinase, FEP+